IBDEI1VL ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33000,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33000,1,3,0)
 ;;=3^Pyonephrosis
 ;;^UTILITY(U,$J,358.3,33000,1,4,0)
 ;;=4^N13.6
 ;;^UTILITY(U,$J,358.3,33000,2)
 ;;=^101552
 ;;^UTILITY(U,$J,358.3,33001,0)
 ;;=N30.91^^182^1994^18
 ;;^UTILITY(U,$J,358.3,33001,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33001,1,3,0)
 ;;=3^Cystitis w/ Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,33001,1,4,0)
 ;;=4^N30.91
 ;;^UTILITY(U,$J,358.3,33001,2)
 ;;=^5015643
 ;;^UTILITY(U,$J,358.3,33002,0)
 ;;=N30.90^^182^1994^19
 ;;^UTILITY(U,$J,358.3,33002,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33002,1,3,0)
 ;;=3^Cystitis w/o Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,33002,1,4,0)
 ;;=4^N30.90
 ;;^UTILITY(U,$J,358.3,33002,2)
 ;;=^5015642
 ;;^UTILITY(U,$J,358.3,33003,0)
 ;;=N41.9^^182^1994^33
 ;;^UTILITY(U,$J,358.3,33003,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33003,1,3,0)
 ;;=3^Inflammatory Disease of Prostate,Unspec
 ;;^UTILITY(U,$J,358.3,33003,1,4,0)
 ;;=4^N41.9
 ;;^UTILITY(U,$J,358.3,33003,2)
 ;;=^5015694
 ;;^UTILITY(U,$J,358.3,33004,0)
 ;;=N70.91^^182^1994^68
 ;;^UTILITY(U,$J,358.3,33004,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33004,1,3,0)
 ;;=3^Salpingitis,Unspec
 ;;^UTILITY(U,$J,358.3,33004,1,4,0)
 ;;=4^N70.91
 ;;^UTILITY(U,$J,358.3,33004,2)
 ;;=^5015806
 ;;^UTILITY(U,$J,358.3,33005,0)
 ;;=N70.93^^182^1994^67
 ;;^UTILITY(U,$J,358.3,33005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33005,1,3,0)
 ;;=3^Salpingitis & Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,33005,1,4,0)
 ;;=4^N70.93
 ;;^UTILITY(U,$J,358.3,33005,2)
 ;;=^5015808
 ;;^UTILITY(U,$J,358.3,33006,0)
 ;;=N70.92^^182^1994^50
 ;;^UTILITY(U,$J,358.3,33006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33006,1,3,0)
 ;;=3^Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,33006,1,4,0)
 ;;=4^N70.92
 ;;^UTILITY(U,$J,358.3,33006,2)
 ;;=^5015807
 ;;^UTILITY(U,$J,358.3,33007,0)
 ;;=N73.9^^182^1994^32
 ;;^UTILITY(U,$J,358.3,33007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33007,1,3,0)
 ;;=3^Inflammatory Disease Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,33007,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,33007,2)
 ;;=^5015820
 ;;^UTILITY(U,$J,358.3,33008,0)
 ;;=A56.11^^182^1994^31
 ;;^UTILITY(U,$J,358.3,33008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33008,1,3,0)
 ;;=3^Inflammatory Disease Chlamydial Female Pelvic
 ;;^UTILITY(U,$J,358.3,33008,1,4,0)
 ;;=4^A56.11
 ;;^UTILITY(U,$J,358.3,33008,2)
 ;;=^5000342
 ;;^UTILITY(U,$J,358.3,33009,0)
 ;;=N73.5^^182^1994^59
 ;;^UTILITY(U,$J,358.3,33009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33009,1,3,0)
 ;;=3^Peritonitis Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,33009,1,4,0)
 ;;=4^N73.5
 ;;^UTILITY(U,$J,358.3,33009,2)
 ;;=^5015817
 ;;^UTILITY(U,$J,358.3,33010,0)
 ;;=N72.^^182^1994^30
 ;;^UTILITY(U,$J,358.3,33010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33010,1,3,0)
 ;;=3^Inflammatory Disease Cervix Uteri
 ;;^UTILITY(U,$J,358.3,33010,1,4,0)
 ;;=4^N72.
 ;;^UTILITY(U,$J,358.3,33010,2)
 ;;=^5015812
 ;;^UTILITY(U,$J,358.3,33011,0)
 ;;=N76.3^^182^1994^84
 ;;^UTILITY(U,$J,358.3,33011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33011,1,3,0)
 ;;=3^Vulvitis,Subacute & Chronic
 ;;^UTILITY(U,$J,358.3,33011,1,4,0)
 ;;=4^N76.3
 ;;^UTILITY(U,$J,358.3,33011,2)
 ;;=^5015829
 ;;^UTILITY(U,$J,358.3,33012,0)
 ;;=N76.1^^182^1994^80
 ;;^UTILITY(U,$J,358.3,33012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33012,1,3,0)
 ;;=3^Vaginitis,Subacute & Chronic
 ;;^UTILITY(U,$J,358.3,33012,1,4,0)
 ;;=4^N76.1
 ;;^UTILITY(U,$J,358.3,33012,2)
 ;;=^5015827
 ;;^UTILITY(U,$J,358.3,33013,0)
 ;;=N76.2^^182^1994^83
 ;;^UTILITY(U,$J,358.3,33013,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI1VL
